| ￥3500 | |
| Z06389 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 36.86 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of TPBG/5T4, His, Mouse is greater than 95% as determined by SEC-HPLC. »
TPBG/5T4, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs. |
| Synonyms | M6P1; 5T4AG; WAIF1; TPBG; 5T4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
